Brought to you by 
Esprit, Novavax end Estrasorb agreement
06 Nov 2007
Executive Summary
Novavax (products for women's health and infectious diseases) has granted Esprit Pharma (women's health therapeutics) an exclusive North American license to Estrasorb (estradiol topical emulsion). The drug is approved for moderate to severe hot flashes that can accompany menopause.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Transdermal
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Esprit, Novavax end Estrasorb agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice